S&P 500   4,587.83 (+0.46%)
DOW   34,547.92 (+0.19%)
QQQ   394.06 (+0.06%)
AAPL   167.41 (+1.28%)
MSFT   334.33 (+1.13%)
FB   316.74 (-2.38%)
GOOGL   2,864.36 (+0.93%)
AMZN   3,479.79 (-0.78%)
TSLA   1,123.58 (-1.85%)
NVDA   321.39 (-1.64%)
BABA   124.46 (-2.41%)
NIO   39.20 (+0.18%)
CGC   10.23 (-4.48%)
AMD   151.44 (-4.38%)
GE   94.63 (-0.38%)
MU   86.63 (+3.13%)
T   22.39 (-1.93%)
F   19.84 (+3.39%)
DIS   144.21 (-0.48%)
PFE   55.12 (+2.59%)
ACB   6.15 (-4.21%)
AMC   30.58 (-9.90%)
BA   192.37 (-2.77%)
S&P 500   4,587.83 (+0.46%)
DOW   34,547.92 (+0.19%)
QQQ   394.06 (+0.06%)
AAPL   167.41 (+1.28%)
MSFT   334.33 (+1.13%)
FB   316.74 (-2.38%)
GOOGL   2,864.36 (+0.93%)
AMZN   3,479.79 (-0.78%)
TSLA   1,123.58 (-1.85%)
NVDA   321.39 (-1.64%)
BABA   124.46 (-2.41%)
NIO   39.20 (+0.18%)
CGC   10.23 (-4.48%)
AMD   151.44 (-4.38%)
GE   94.63 (-0.38%)
MU   86.63 (+3.13%)
T   22.39 (-1.93%)
F   19.84 (+3.39%)
DIS   144.21 (-0.48%)
PFE   55.12 (+2.59%)
ACB   6.15 (-4.21%)
AMC   30.58 (-9.90%)
BA   192.37 (-2.77%)
S&P 500   4,587.83 (+0.46%)
DOW   34,547.92 (+0.19%)
QQQ   394.06 (+0.06%)
AAPL   167.41 (+1.28%)
MSFT   334.33 (+1.13%)
FB   316.74 (-2.38%)
GOOGL   2,864.36 (+0.93%)
AMZN   3,479.79 (-0.78%)
TSLA   1,123.58 (-1.85%)
NVDA   321.39 (-1.64%)
BABA   124.46 (-2.41%)
NIO   39.20 (+0.18%)
CGC   10.23 (-4.48%)
AMD   151.44 (-4.38%)
GE   94.63 (-0.38%)
MU   86.63 (+3.13%)
T   22.39 (-1.93%)
F   19.84 (+3.39%)
DIS   144.21 (-0.48%)
PFE   55.12 (+2.59%)
ACB   6.15 (-4.21%)
AMC   30.58 (-9.90%)
BA   192.37 (-2.77%)
S&P 500   4,587.83 (+0.46%)
DOW   34,547.92 (+0.19%)
QQQ   394.06 (+0.06%)
AAPL   167.41 (+1.28%)
MSFT   334.33 (+1.13%)
FB   316.74 (-2.38%)
GOOGL   2,864.36 (+0.93%)
AMZN   3,479.79 (-0.78%)
TSLA   1,123.58 (-1.85%)
NVDA   321.39 (-1.64%)
BABA   124.46 (-2.41%)
NIO   39.20 (+0.18%)
CGC   10.23 (-4.48%)
AMD   151.44 (-4.38%)
GE   94.63 (-0.38%)
MU   86.63 (+3.13%)
T   22.39 (-1.93%)
F   19.84 (+3.39%)
DIS   144.21 (-0.48%)
PFE   55.12 (+2.59%)
ACB   6.15 (-4.21%)
AMC   30.58 (-9.90%)
BA   192.37 (-2.77%)
NASDAQ:AXDX

Accelerate Diagnostics Stock Forecast, Price & News

$4.91
-0.09 (-1.80%)
(As of 12/1/2021 02:12 PM ET)
Add
Compare
Today's Range
$4.89
$5.26
50-Day Range
$4.96
$6.97
52-Week Range
$4.78
$15.60
Volume
10,704 shs
Average Volume
347,313 shs
Market Capitalization
$301.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.8
30 days | 90 days | 365 days | Advanced Chart
Receive AXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.


Accelerate Diagnostics logo

About Accelerate Diagnostics

Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The firm's products include Accelerate Pheno and Accelerate PhenoTest. The company was founded on May 26, 1982 and is headquartered in Tucson, AZ.

Headlines

What Wall Street expects from Accelerate Diagnostics's earnings
November 9, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXDX
Employees
224
Year Founded
N/A

Sales & Book Value

Annual Sales
$11.16 million
Book Value
($1.06) per share

Profitability

Net Income
$-78.21 million
Net Margins
-639.62%
Pretax Margin
-639.68%

Debt

Price-To-Earnings

Miscellaneous

Free Float
33,640,000
Market Cap
$301.96 million
Optionable
Optionable

Company Calendar

Last Earnings
11/09/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/22/2022

MarketRank

Overall MarketRank

2.73 out of 5 stars

Medical Sector

46th out of 1,392 stocks

Analytical Instruments Industry

1st out of 33 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -












Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions

Is Accelerate Diagnostics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Accelerate Diagnostics stock.
View analyst ratings for Accelerate Diagnostics
or view top-rated stocks.

How has Accelerate Diagnostics' stock been impacted by Coronavirus?

Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AXDX stock has decreased by 53.6% and is now trading at $4.92.
View which stocks have been most impacted by COVID-19
.

When is Accelerate Diagnostics' next earnings date?

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Accelerate Diagnostics
.

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) posted its quarterly earnings results on Tuesday, November, 9th. The medical research company reported ($0.15) EPS for the quarter, beating the Zacks' consensus estimate of ($0.35) by $0.20. The medical research company earned $3.12 million during the quarter, compared to analysts' expectations of $3.51 million. During the same period in the previous year, the firm earned ($0.33) EPS.
View Accelerate Diagnostics' earnings history
.

What price target have analysts set for AXDX?

1 equities research analysts have issued 1-year price objectives for Accelerate Diagnostics' shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate Accelerate Diagnostics' share price to reach $9.00 in the next twelve months. This suggests a possible upside of 82.9% from the stock's current price.
View analysts' price targets for Accelerate Diagnostics
or view top-rated stocks among Wall Street analysts.

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the following people:

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Oracle Investment Management Inc. (6.10%), BlackRock Inc. (3.79%), AXA S.A. (2.58%), Griffin Asset Management Inc. (2.04%), Chicago Capital LLC (0.95%) and Geode Capital Management LLC (0.88%). Company insiders that own Accelerate Diagnostics stock include Hany Massarany, Jack Phillips, Jack W Schuler, Romney Humphries, Ron Price and Steven Reichling.
View institutional ownership trends for Accelerate Diagnostics
.

Which institutional investors are selling Accelerate Diagnostics stock?

AXDX stock was sold by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Griffin Asset Management Inc., Two Sigma Advisers LP, AXA S.A., Goldman Sachs Group Inc., Geode Capital Management LLC, Oracle Investment Management Inc., and Rafferty Asset Management LLC. Company insiders that have sold Accelerate Diagnostics company stock in the last year include Jack Phillips, Ron Price, and Steven Reichling.
View insider buying and selling activity for Accelerate Diagnostics
or view top insider-selling stocks.

Which institutional investors are buying Accelerate Diagnostics stock?

AXDX stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, GSA Capital Partners LLP, Thompson Investment Management Inc., Marshall Wace LLP, Cubist Systematic Strategies LLC, SG Americas Securities LLC, Two Sigma Investments LP, and Keebeck Alpha LP. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Hany Massarany, Jack W Schuler, and Steven Reichling.
View insider buying and selling activity for Accelerate Diagnostics
or or view top insider-buying stocks.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $4.92.

How much money does Accelerate Diagnostics make?

Accelerate Diagnostics has a market capitalization of $302.58 million and generates $11.16 million in revenue each year. The medical research company earns $-78.21 million in net income (profit) each year or ($1.25) on an earnings per share basis.

How many employees does Accelerate Diagnostics have?

Accelerate Diagnostics employs 224 workers across the globe.

What is Accelerate Diagnostics' official website?

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

Where are Accelerate Diagnostics' headquarters?

Accelerate Diagnostics is headquartered at 3950 South Country Club Suite 470, Tucson AZ, 85714.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at (520) 365-3100, via email at [email protected], or via fax at 520-269-6580.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.